| Literature DB >> 26977886 |
Hye-Jung E Chun1, Emilia L Lim1, Alireza Heravi-Moussavi1, Saeed Saberi2, Karen L Mungall1, Mikhail Bilenky1, Annaick Carles2, Kane Tse1, Inna Shlafman1, Kelsey Zhu1, Jenny Q Qian1, Diana L Palmquist1, An He1, William Long1, Rodrigo Goya1, Michelle Ng1, Veronique G LeBlanc1, Erin Pleasance1, Nina Thiessen1, Tina Wong1, Eric Chuah1, Yong-Jun Zhao1, Jacquie E Schein1, Daniela S Gerhard3, Michael D Taylor4, Andrew J Mungall1, Richard A Moore1, Yussanne Ma1, Steven J M Jones5, Elizabeth J Perlman6, Martin Hirst7, Marco A Marra8.
Abstract
Malignant rhabdoid tumors (MRTs) are rare lethal tumors of childhood that most commonly occur in the kidney and brain. MRTs are driven by SMARCB1 loss, but the molecular consequences of SMARCB1 loss in extra-cranial tumors have not been comprehensively described and genomic resources for analyses of extra-cranial MRT are limited. To provide such data, we used whole-genome sequencing, whole-genome bisulfite sequencing, whole transcriptome (RNA-seq) and microRNA sequencing (miRNA-seq), and histone modification profiling to characterize extra-cranial MRTs. Our analyses revealed gene expression and methylation subgroups and focused on dysregulated pathways, including those involved in neural crest development.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26977886 PMCID： PMC5094835 DOI： 10.1016/j.ccell.2016.02.009
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743